Sandoz to Commercialize Samsung Bioepis' Biosimilar to J&J's Stelara

As the Novartis generics and biosimilars division nears its spin-off, Sandoz has signed a commercialization agreement with Samsung Bioepis, gaining rights to the latter’s Stelara biosimilar.

Related Keywords

Canada ,Switzerland ,Swiss ,Sandoz Samsung Bioepsis ,Richard Saynor ,Johnson Stelara ,Samsung Bioepis ,Polpharma Biologics ,Biocon ,Novartis ,Amgen ,Bio Thera Solutions ,European Economic ,Resume ,Careers ,Andoz To Commercialize Samsung Bioepis Biosimilar Toj Ampjs Stelara ,Iospace ,Advice ,